...
首页> 外文期刊>Global heart >MS09.2 Empagliflozin Reduces Mortality In Patients With Type 2 Diabetes and A History of Left Ventricular Hypertrophy: A Sub-analysis of the EMPA-REG OUTCOME Trial
【24h】

MS09.2 Empagliflozin Reduces Mortality In Patients With Type 2 Diabetes and A History of Left Ventricular Hypertrophy: A Sub-analysis of the EMPA-REG OUTCOME Trial

机译:MS09.2 Empagliflozin降低了2型糖尿病患者的死亡率和左心室肥大的历史:EMPA-REG结果试验的分析

获取原文
获取原文并翻译 | 示例
           

著录项

  • 来源
    《Global heart》 |2018年第4期|共1页
  • 作者单位

    St Michael's Hospital Division of Cardiac Surgery University of Toronto;

    St Michael's Hospital Department of Anesthesia University of Toronto;

    Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School;

    Department of Cardiac Sciences Libin Cardiovascular Institute of Alberta University of Calgary;

    St Michael's Hospital Division of Cardiology University of Toronto;

    St Michael's Hospital Division of Cardiac Surgery University of Toronto;

    University of Pisa School of Medicine;

    Boehringer Ingelheim International GmbH;

    Lunenfeld-Tanenbaum Research Institute Mount Sinai Hospital University of Toronto;

    St Michael's Hospital Division of Cardiology University of Toronto;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 心脏、血管(循环系)疾病;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号